The HMGXB4 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line. This loss-of-function model targets HMGXB4, a chromatin-associated transcriptional regulator, and is provided as a heterogeneous population enriched for gene disruptions. The polyclonal format allows assessment of overall gene function without clonal selection bias, suitable for physiologically relevant phenotypic studies.
HT29 cells were derived from a primary colorectal adenocarcinoma in a 44-year-old Caucasian female and are an established intestinal epithelial cell model for cancer biology and drug absorption research. These cells form tight junctions, express characteristic enterocyte markers, and maintain functional epithelial barrier properties. Importantly, HT29 cells harbor wild-type APC and a responsive Wnt/??-catenin signaling axis, making them informative for studying pathways dysregulated in colorectal cancer.
HMGXB4 functions as a DNA-binding chromatin organizer that regulates expression of genes involved in cell adhesion and migration. It interacts with ??-catenin and TCF/LEF transcription factors, integrating Wnt/??-catenin signals, and participates in TGF-?? signaling via associations with SMAD2/3 complexes downstream of TGF-?? receptors. Through these interactions, HMGXB4 transcriptionally controls EMT markers such as E-cadherin (CDH1) and vimentin (VIM), directly impacting cell adhesion and motility.
In the HT29 context, knockout of HMGXB4 offers a powerful system to dissect its contribution to colorectal cancer progression and EMT. Given the cells?? inherent tendency to form cohesive monolayers, HMGXB4 disruption is expected to weaken cell-cell contacts, increase migratory and invasive capacity, and modulate responses to microenvironmental cues. This model enables mechanistic dissection of how HMGXB4-dependent chromatin remodeling influences the epithelial-to-mesenchymal transition in colorectal adenocarcinoma.
Applications include western blotting and RT-qPCR to confirm knockout and assess downstream targets CDH1 and VIM; scratch migration and Transwell invasion assays to evaluate motility and invasiveness; immunofluorescence for EMT marker localization; proliferation and TEER assays for barrier function; and drug target validation. For further details or custom applications, please contact Ascent Research.
